JP2021513328A5 - - Google Patents

Info

Publication number
JP2021513328A5
JP2021513328A5 JP2020541758A JP2020541758A JP2021513328A5 JP 2021513328 A5 JP2021513328 A5 JP 2021513328A5 JP 2020541758 A JP2020541758 A JP 2020541758A JP 2020541758 A JP2020541758 A JP 2020541758A JP 2021513328 A5 JP2021513328 A5 JP 2021513328A5
Authority
JP
Japan
Prior art keywords
antibody
disease
ms4a6a
group
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020541758A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021513328A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/016141 external-priority patent/WO2019152706A1/en
Publication of JP2021513328A publication Critical patent/JP2021513328A/ja
Publication of JP2021513328A5 publication Critical patent/JP2021513328A5/ja
Priority to JP2023095282A priority Critical patent/JP2023113896A/ja
Pending legal-status Critical Current

Links

JP2020541758A 2018-01-31 2019-01-31 抗ms4a6a抗体及びその使用方法 Pending JP2021513328A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023095282A JP2023113896A (ja) 2018-01-31 2023-06-09 抗ms4a6a抗体及びその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862624578P 2018-01-31 2018-01-31
US62/624,578 2018-01-31
US201862646846P 2018-03-22 2018-03-22
US62/646,846 2018-03-22
PCT/US2019/016141 WO2019152706A1 (en) 2018-01-31 2019-01-31 Anti-ms4a6a antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023095282A Division JP2023113896A (ja) 2018-01-31 2023-06-09 抗ms4a6a抗体及びその使用方法

Publications (2)

Publication Number Publication Date
JP2021513328A JP2021513328A (ja) 2021-05-27
JP2021513328A5 true JP2021513328A5 (cg-RX-API-DMAC7.html) 2022-02-07

Family

ID=67479397

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020541758A Pending JP2021513328A (ja) 2018-01-31 2019-01-31 抗ms4a6a抗体及びその使用方法
JP2023095282A Pending JP2023113896A (ja) 2018-01-31 2023-06-09 抗ms4a6a抗体及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023095282A Pending JP2023113896A (ja) 2018-01-31 2023-06-09 抗ms4a6a抗体及びその使用方法

Country Status (5)

Country Link
US (2) US20210122817A1 (cg-RX-API-DMAC7.html)
EP (1) EP3746484A4 (cg-RX-API-DMAC7.html)
JP (2) JP2021513328A (cg-RX-API-DMAC7.html)
CN (1) CN112204050B (cg-RX-API-DMAC7.html)
WO (1) WO2019152706A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3746476A1 (en) 2018-01-31 2020-12-09 Alector LLC Anti-ms4a4a antibodies and methods of use thereof
EP3746484A4 (en) 2018-01-31 2021-11-17 Alector LLC ANTI-MS4A6A ANTIBODY AND METHOD OF USING THEREOF
PH12022550239A1 (en) 2019-07-31 2022-12-19 Alector Llc Anti-ms4a4a antibodies and methods of use thereof
CA3231484A1 (en) 2021-10-01 2023-04-06 Qinwen Mao Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy
CN115029383B (zh) * 2022-04-21 2024-02-20 苏天生命科技(苏州)有限公司 Ms4a3蛋白在调控红细胞成熟中的应用
CN116219009B (zh) * 2022-10-19 2024-10-01 杭州师范大学 小胶质细胞特异性表达的ms4a6a在胶质母细胞瘤治疗或预后评估试剂盒上的应用
AU2024370996A1 (en) * 2023-10-30 2026-05-14 Regeneron Pharmaceuticals, Inc. Treatment of myeloid cell dysfunction with membrane spanning 4-domains a6a (ms4a6a) inhibitors

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
WO1997011971A1 (en) 1995-09-28 1997-04-03 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
AU2002251692A1 (en) 2000-12-08 2002-08-19 Duke University Identification of novel ms4a gene family members expressed by hematopoietic cells
GB0125338D0 (en) 2001-10-22 2001-12-12 Isis Innovation Process for reducing immunogenic reactions using selective TH1 cell binding antibodies
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
KR20050000380A (ko) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
WO2003085102A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
GB0324888D0 (en) 2003-10-24 2003-11-26 Novartis Ag Organic compounds
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
AU2005255024C1 (en) * 2004-06-14 2010-09-09 The Board Of Trustees Of The University Of Illinois Antibodies binding to CD34+/CD36+ fetal but not to adult cells
CN101001879A (zh) 2004-06-14 2007-07-18 伊利诺伊大学董事会 与胎儿而非成体cd34+/cd36+细胞结合的抗体
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
HUE066795T2 (hu) 2006-03-15 2024-09-28 Alexion Pharma Inc Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral
EP2016101A2 (en) 2006-05-09 2009-01-21 Genentech, Inc. Binding polypeptides with optimized scaffolds
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
GB0624500D0 (en) 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
EP2108701A1 (en) 2008-04-10 2009-10-14 Ganymed Pharmaceuticals AG Methods involving MS4A12 and agents targeting MS4A12 for therapy, diagnosis and testing
EP2390349A1 (en) * 2010-05-25 2011-11-30 Sanofi Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
CN104774264B (zh) * 2014-01-15 2018-09-14 上海易乐生物技术有限公司 抗人proBDNF单克隆抗体及其在疼痛中的作用
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
US20190321443A1 (en) * 2016-02-16 2019-10-24 President And Fellows Of Harvard College Modulators of MS4A activity
CN105759057A (zh) * 2016-04-12 2016-07-13 上海凯璟生物科技有限公司 一种检测阿尔兹海默综合症ms4a6a的干式免疫荧光试剂盒和制备方法
CN105969901B (zh) * 2016-07-27 2019-10-11 北京泱深生物信息技术有限公司 Ms4a6a作为多发性骨髓瘤诊治标志物的用途
EP3746484A4 (en) 2018-01-31 2021-11-17 Alector LLC ANTI-MS4A6A ANTIBODY AND METHOD OF USING THEREOF
EP3746476A1 (en) 2018-01-31 2020-12-09 Alector LLC Anti-ms4a4a antibodies and methods of use thereof
US20220133808A1 (en) 2019-02-01 2022-05-05 Avrobio, Inc. Compositions and methods for treating neurocognitive disorders
PH12022550239A1 (en) 2019-07-31 2022-12-19 Alector Llc Anti-ms4a4a antibodies and methods of use thereof
CN114599393A (zh) 2019-10-22 2022-06-07 比奥根Ma公司 治疗阿尔茨海默病的抗β-淀粉样蛋白抗体
WO2024086796A1 (en) 2022-10-20 2024-04-25 Alector Llc Anti-ms4a4a antibodies with amyloid-beta therapies

Similar Documents

Publication Publication Date Title
JP2021513329A5 (cg-RX-API-DMAC7.html)
JP2020533948A5 (cg-RX-API-DMAC7.html)
JP2022542964A5 (cg-RX-API-DMAC7.html)
HRP20230675T1 (hr) Anti-trem2 protutijela i postupci njihove uporabe
JP7862028B2 (ja) 免疫細胞活性化のための二重特異性抗体
JP2020532947A5 (cg-RX-API-DMAC7.html)
JP2017523814A5 (cg-RX-API-DMAC7.html)
US20260132202A1 (en) Bispecific antibodies that bind pd-l1 and cd28
JP6844719B2 (ja) 二重特異性抗体
JP2021530960A5 (cg-RX-API-DMAC7.html)
JP7476997B2 (ja) 二重特異性抗体
JP2021529520A5 (cg-RX-API-DMAC7.html)
JP2020531043A (ja) 抗4−1bb抗体とその作製及び使用方法
JP2022525478A5 (cg-RX-API-DMAC7.html)
CA2646965A1 (en) Engineered heterodimeric protein domains
JP2021516951A5 (cg-RX-API-DMAC7.html)
TW202233674A (zh) 用於調節δγ鏈介導之免疫的組成物及方法
JP2021531027A5 (cg-RX-API-DMAC7.html)
JP7688805B2 (ja) 二重特異性抗体
JP2024541476A5 (cg-RX-API-DMAC7.html)
US20250043001A1 (en) Anti-cd28 compositions
JP2018502068A5 (cg-RX-API-DMAC7.html)
TW202221015A (zh) 單一及雙靶定配體誘導之t細胞銜接體組合物
JP7574692B2 (ja) 二重特異性抗体
JP2012506237A (ja) Dc−signに対する結合特異性をもつリガンド